AstraZeneca Data Summary 2020

3



Access to healthcare (including Investment in health systems)

Targets


People reached¹

2025 target

Reach 50 million people (cumulatively) through Healthy Heart Africa, Young Health Programme (YHP), Healthy Lung and Phakamisa programmes.

2020 update

More than 25 million people reached (cumulatively) through Healthy Heart Africa, YHP, Phakamisa and Healthy Lung programmes. This target has been modified to double the people reached and now encompasses four Access to healthcare programmes.





Healthcare workers trained¹

2025 target

Train 170,000 healthcare workers (cumulatively) to strengthen health systems throughout the world through our Healthy Heart Africa, Healthy Lung, Phakamisa programmes and Young Health Programme.

2020 update


More than 132,000 healthcare workers trained (cumulatively). The previous target of 75,000 was achieved in 2019.




Status: On plan

Highlights

People reached by Access to healthcare programmes (cumulative)



Healthcare workers trained (cumulative)



Please see more information on p.4

KPIs

111 10				
People reached by access to healthcare programmes (cumulative), million ²	SDG	2018	2019	2020
Healthy Heart Africa	3.4	9.970	13.522	16.675
Phakamisa ³	3.4	1.480	1.629	1.629
Healthy Lung Asia⁴	3.4	0.531	1.213	1.539
Healthy Lung Gulf ⁵	3.4	0.001	0.0004	0.00046
Healthy Lung Mexico	3.4	0.024	0.036	0.037
Healthy Lung Saudi Arabia ⁷	3.4	N/A	0.065	0.065
Healthy Lung Egypt ⁸	3.4	N/A	0.007	0.011
Young Health Programme	3.4	3.01	4.01	5.07
TOTAL PEOPLE REACHED (all programmes)	3.4	15.016	20.482	25.026
Health facilities activated (cumulative)	SDG	2018	2019	2020
Healthy Heart Africa	3.8	706	780	824
Healthy Lung Asia⁴	3.8	911	1,646	2,055
Healthy Lung Gulf⁵	3.8	2	5	5
Healthy Lung Mexico	3.8	380	408	408
Healthy Lung Saudi Arabia ⁷	3.8	3	15	15
Healthy Lung Egypt ⁸	3.8	N/A	41	56
TOTAL (all programmes)	3.8	2,002	2,895	3,363
Healthcare workers trained (cumulative)	SDG	2018	2019	2020
Healthy Heart Africa	3с	5,818	7,280	7,361
Phakamisa — Physicians and Nurses ³	3с	762	762	762
Phakamisa — Navigator Volunteers ³	3с	523	523	523
Healthy Lung Asia4	3с	26,121	57,562	79,806
Healthy Lung Gulf ⁵	3с	540	2,283	4,783
Healthy Lung Mexico	3с	584	1,135	1,135
Healthy Lung Saudi Arabia ⁷	3с	1,540	15,938	17,012
Healthy Lung Egypt ⁸	3с	N/A	330	330
Young Health Programme	3с	18,821 ⁹	20,345°	20,533
TOTAL (all programmes)	3c	54,709	106,158	132,245

AstraZeneca Data Summary 2020

9



Greenhouse gas reduction

Targets

Highlights

Scope 3 value chain

2025 target

Reduce Scope 3 intensity by 25% from 2015 to 2025.


2020 update

The launch of our Ambition Zero Carbon 2030 carbon negative goal supersedes this target.



Status: On plan

Scope 3 intensity (tCO₂e per million USD of revenue)



Primary data for Scope 3 reporting

2025 target

Increase the share of primary activity data in our Scope 3 reporting.


2020 update

Reduction to 16% Scope 3 primary data, from 20% in 2019.



Status: On plan

Primary data (Scope 3)



Next-generation inhaler

2025 target

Launch a next-generation inhaler to treat asthma and Chronic Obstructive Pulmonary Disease (COPD) with near zero Global Warming Potential (GWP) propellant.

2020 update

We progressed a project spanning all key functions in the business to investigate alternative low-GWP propellant options from an environmental, technical, regulatory, medical, non-clinical and commercial viewpoint.






KPIs

Scope 3 categories (tCO _z e)	2015 baseline	2018	2019	2020	2020 primary data
Category 1 - Purchased goods and services ⁷	5,853,811	4,555,560	4,933,826	5,767,108	0%
Category 2 - Capital goods	93,024	77,647	116,017	116,059	0%
Category 3 - Fuel and energy- related ⁸	99,310³	82,855 ³	78,019³	50,360	100%
Category 4 - Upstream transportation and distribution ⁹	199,858	327,344	275,557	247,961	43%
Category 5 - Waste generated in operations	23,507	24,682	25,019	24,901	100%
Category 6 - Business travel ¹⁰	177,483	217,975	281,967	80,804	81%
Category 7 - Employee commuting ¹¹	23,338	20,751	27,058	35,211	0%
Category 8 - Upstream leased assets	23,243	29,067	25,400	46,060	0%
Category 9 - Downstream transportation and distribution	316,081	296,430	404,203	377,767	0%
Category 10 – Processing of sold products	Assessed: Not relevant				
Category 11 - Use of sold products	706,936 ³	869,137 ³	1,012,7323	978,895	100%
Category 12 - End of life treatment of sold products	23,508	89,036	77,266	72,072	0%
Category 13 – Downstream leased assets	956	12,592	25,047	5,947	0%
Category 14 – Franchises	Assessed: Not relevant				
Category 15 - Investments	Assessed: Not relevant				
Total Scope 3 footprint	7,541,056	6,603,075	7,282,111	7,803,145	16%
Scope 3 intensity (tCO ₂ e per million USD of revenue)	305.21	298.92	298.64	293.16	

AstraZeneca Data Summary 2020

20



Targets

Highlights

Positive Sourcing Programme¹⁴

2025 target

Embed sustainability into our end-to-end procurement processes through our Positive Sourcing Programme.

2020 update

updated to incorporate our sustainability priorities in line with the PSCI principles.

Sustainability has been included as a required component of all category strategies.¹⁵

piloted across multiple categories, planned to be implemented enterprise wide.



Piloted sustainability assessment platform EcoVadis



Status: On plan

Sustainability Partner Guide and Framework16

2025 target

75% of all critical manufacturing partner sites are rated 'bronze' or better in our Sustainability Partner Guide and Framework.


2020 update

64% (67 of 105 supplier sites) of critical manufacturing partners achieved 'bronze' or better in our Sustainability Partner Guide and Framework.



Status: On plan

Overall Sustainability Partner Guide and Framework performance



KPIs

Responsible supply chain	SDG	2018	2019	2020
Total supplier assessments ¹⁷	8.8	12,967	15,519	16,197
High-risk supplier audits		45	38	48 ¹⁸
Critical manufacturing suppliers that disclose their energy, waste and water footprint	12.6	27%	60.7%19	61.3%
Critical manufacturing partner sites with Sustainability Partner Guide and Framework rating of 'bronze' or better		N/A	N/A	64%
PSCI environmental sustainability assessments completed		74	72	66
Countries with supplier diversity programmes		1	2	4

Supply chain – environmental footprint for critical direct suppliers ²⁰	2018	2019	2020
AstraZeneca manufacturing sites — total waste (thousand tonnes)	26 ²¹	27 ²¹	30
API category — total waste (thousand tonnes)	39	35	66
Formulation & Packaging (F&P) category — total waste (thousand tonnes)	10	4	3
AstraZeneca manufacturing sites — water use (million m³)	3.21 ²¹	3.30 ²¹	2.96
API category — water use (million m³)	1.3	0.7	1.4
F&P category — water use (million m³)	1.0	0.6	0.3

Supply chain – CO ₂ footprint for critical direct suppliers ²⁰	2018	2019	2020
AstraZeneca manufacturing sites $-CO_2$ from energy (thousand tonnes)	262 ²¹	251 ²¹	232
API category — CO ₂ from energy (thousand tonnes)	91	70	72
F&P category — CO ₂ from energy (thousand tonnes)	72	45	42